All In Biotech

Drug Trial Radar · NCT05621317

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Actual

Start

Feb 9, 2023

Primary completion

Sep 26, 2025

Study completion Jun 2028

Sponsor

Lead sponsor
Aravax Pty LtdIndustry
Sponsor type
Industry
First posted
Nov 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

Conditions

  • Peanut Allergy
  • Peanut Hypersensitivity
  • Peanut-Induced Anaphylaxis
  • Immune System Diseases

Interventions

  • PVX-108Biological

    PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

  • PlaceboBiological

    Matching placebo comprises the formulation vehicle without peptides

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of maximum tolerated dose (MTD) of peanut protein at the Week 46 double blind placebo-controlled food challenge (DBPCFC) relative to baseline in children aged 4 to 11 years treated with PVX108 compared to placeboTime frame: 46 weeks

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Research Institute

    Little Rock, Arkansas

  • Peninsula Research Associates

    Rolling Hills Estates, California

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Riley Children's Hospital at IU

    Indianapolis, Indiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • IAA Clinical Research

    Chevy Chase, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Women's and Children's Hospital

    North Adelaide, South Australia, Australia

  • The Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.